01—Abstract
Summary
Summary of the 10-K filed February 12, 2015. Cited figures are marked; the original filing is the authoritative source.
Stryker Corporation's 2014 Form 10-K reveals a company with robust revenue growth, achieving $9.675 billiona in net sales, a 7.3% increase year-over-year.
This growth was driven by strong performance across its three key segments: Orthopaedics, MedSurg, and Neurotechnology and Spine, with particular strength noted in instruments, trauma and extremities, and neurotechnology products. The company continued its strategic focus on acquisitions, investing $916 millionb in 2014 to expand its product offerings and market reach. However, net earnings experienced a significant decline of 48.8% to $515 million, largely impacted by substantial recall charges related to hip stems, totaling $761 million.
Despite this, Stryker maintained a strong financial position with $5 billionc in cash, cash equivalents, and marketable securities, indicating good liquidity. The company also demonstrated its commitment to returning value to shareholders through dividend payments and share repurchases, while continuing to invest in research and development to fuel future innovation.
02—Key points
Key Highlights
- Stryker reported 2014 net sales of $9.675 billion, an increase of 7.3% over 2013, indicating strong top-line growth.
- The company made significant strategic acquisitions in 2014, including SBi ($358M), Berchtold ($184M), and PST ($120M), to enhance its product portfolio.
- Net earnings saw a substantial decrease of 48.8% to $515 million, primarily due to significant recall charges related to the Rejuvenate and ABG II hip stems, amounting to $761 million.
- The company's cash position remained strong, with $5 billion in cash, cash equivalents, and marketable securities at year-end 2014, providing ample liquidity.
- Stryker continued to return capital to shareholders through dividends ($462M paid in 2014) and share repurchases ($100M in 2014).
- Research, development, and engineering expenses increased to 6.3% of sales in 2014, reflecting continued investment in innovation.
- The company managed its debt effectively, increasing total debt to $3.973 billion in 2014, primarily to fund acquisitions and other strategic initiatives.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2014, Stryker Corp kept $0.05.
- Revenue$9.68B100.0%
- Cost of revenue−$3.32B34.3%
- Gross profit$6.36B65.7%
- Operating costs−$5.11B52.8%
- Operating income$1.25B12.9%
- Interest, other & tax−$731.0M7.6%
- Net income$515.0M5.3%
Where FY2014 revenue went
$9.68B- SG&A: $3.55B, 37% of revenue
- Cost of revenue: $3.32B, 34% of revenue
- Net income: $515.0M, 5.3% of revenue
- R&D: $614.0M, 6.3% of revenue
- Other operating costs: $949.0M, 9.8% of revenue
- Interest, other & tax: $731.0M, 7.6% of revenue
Kept 5.3% as net incomeNet income $515.0M · 5.3%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2014filed February 12, 2015Financial Statements
FY2014 against FY2013
| Line item | FY2014FY2013 | Change |
|---|---|---|
| Revenue | $9.68B$9.02B | +7.2% |
| Cost of Revenue | $3.32B$3.00B | +10.6% |
| Gross Profit | $6.36B$6.02B | +5.6% |
| R&D Expenses | $614.00M$536.00M | +14.6% |
| SG&A Expenses | $3.55B$3.47B | +2.3% |
| Operating Expenses | $5.11B$4.76B | +7.3% |
| Operating Income | $1.25B$1.26B | −0.8% |
| Interest Expense | $113.00M$83.00M | +36.1% |
| Net Income | $515.00M$1.01B | −48.8% |
| EPS (Basic) | $1.36$2.66 | −48.9% |
| EPS (Diluted) | $1.34$2.63 | −49.0% |
| Shares Outstanding (Basic) | 378.50M378.60M | 0.0% |
| Shares Outstanding (Diluted) | 382.80M382.10M | +0.2% |
05—Questions
Frequently Asked Questions
What was Stryker's revenue performance in 2014, and what drove it?
Stryker reported 2014 net sales of $9.675 billion, a 7.3% increase from 2013. This growth was driven by higher unit volumes across its Orthopaedics, MedSurg, and Neurotechnology and Spine segments, bolstered by strategic acquisitions made during the year. Key product areas contributing to the growth included instruments, trauma and extremities, and neurotechnology.
What is the reason for the significant decrease in net earnings in 2014?
The substantial decrease in net earnings in 2014 was primarily due to significant recall charges related to the Rejuvenate and ABG II hip stems. These recall charges, net of insurance recoveries, amounted to $761 million, significantly impacting the company's profitability for the year.
How did Stryker manage its financial resources and capital allocation in 2014?
Stryker maintained a strong liquidity position with $5 billion in cash, cash equivalents, and marketable securities. Its capital allocation strategy prioritized acquisitions, deploying $916 million for strategic purchases, followed by dividend payments ($462 million) and share repurchases ($100 million). The company also increased its debt to $3.973 billion to support these activities.
What are the key risks and uncertainties facing Stryker as outlined in the filing?
Stryker faces several risks, including uncertainty surrounding the impact of U.S. healthcare reform legislation and its associated excise tax on medical devices. Product liability claims, particularly those related to past hip stem recalls, remain a significant concern. The company is also exposed to risks associated with intense competition, intellectual property litigation, stringent government regulations, and the complexities of its extensive international operations, including currency exchange rate fluctuations.
06—Continue